Type 2 Diabetes and HDL Dysfunction: A Key Contributor to Glycemic Control.

Area of Science:

• Cardiovascular Medicine
• Metabolic Disorders
• Pharmacology

Background:

• High-density lipoproteins (HDL) possess cardioprotective and antidiabetic functions, including cholesterol efflux, antioxidant, anti-inflammatory, and antiapoptotic properties.
• Type 2 diabetes (T2D) is characterized by low HDL cholesterol (HDL-C) and impaired HDL functionality, negatively affecting pancreatic beta-cell function and insulin sensitivity.
• Impaired HDL function is linked to reduced ATP-binding cassette transporter A1-mediated efflux to apolipoprotein A-I.

Purpose of the Study:

• To explore the role of HDL functionality in T2D.
• To evaluate the potential of HDL-based therapies for improving glycemic control in T2D.

Main Methods:

• Review of existing literature on HDL function in T2D.
• Analysis of experimental interventions, including synthetic HDL and apolipoprotein A-I infusions.
• Examination of posthoc analyses of clinical trials involving cholesteryl ester transfer protein (CETP) inhibitors.

Main Results:

• Experimental interventions aimed at enhancing HDL function improved glycemic control in T2D models and patients.
• CETP inhibitors, designed to increase HDL-C and HDL function, demonstrated potential anti-diabetic properties in clinical trials.

Conclusions:

• HDL dysfunction contributes to the pathophysiology of T2D.
• Targeting HDL functionality through therapies like CETP inhibitors represents a promising strategy for improving glycemic control in T2D.
• Further research into HDL functionality and therapies is crucial for advancing T2D management.